IL-6 blockade or anti-IL-6R monoclonal antibody reversed the effect of ICIs in HCC, colorectal cancer, melanoma, triple negative breast cancer, and squamous cell carcinoma, along with marked reduction of MDSCs, decreased suppressive activity of MDSCs, or an increase in tumor infiltrating CD8+ effector T cells (153–157). This evidence concerns the gene CD8A and neoplasm.